{"id":"placebo-saxagliptin","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Muscle pain"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2103745","moleculeType":"Small molecule","molecularWeight":"333.43"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This action results in a decrease in blood glucose levels. Saxagliptin is used in combination with other medications to improve glycemic control in patients with type 2 diabetes. It is also used as a placebo in clinical trials to compare its efficacy with active treatments.","oneSentence":"Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which works by increasing the levels of incretin hormones to stimulate the release of insulin and decrease the release of glucagon.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:21.945Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT02285985","phase":"PHASE4","title":"Effects of Saxagliptin on Adipose Tissue Inflammation in Humans","status":"COMPLETED","sponsor":"Phoenix VA Health Care System","startDate":"2013-02","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":103},{"nctId":"NCT03199053","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-10-11","conditions":"Diabetes Mellitus, Type 2","enrollment":256},{"nctId":"NCT03660683","phase":"PHASE4","title":"Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Sabyasachi Sen","startDate":"2018-10-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":15},{"nctId":"NCT01527747","phase":"PHASE4","title":"Effects of DPP-4 Inhibition on Triglycerides","status":"SUSPENDED","sponsor":"Oregon Health and Science University","startDate":"2012-01","conditions":"Type 2 Diabetes, Hypertriglyceridemia","enrollment":15},{"nctId":"NCT03608358","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2019-02-27","conditions":"Type 2 Diabetes Mellitus","enrollment":41},{"nctId":"NCT02917031","phase":"PHASE4","title":"Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-01-10","conditions":"Type 2 Diabetes Mellitus, Heart Failure","enrollment":348},{"nctId":"NCT02597101","phase":"PHASE2","title":"Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes","status":"COMPLETED","sponsor":"Nick Giannoukakis, PhD","startDate":"2015-11","conditions":"Type 2 Diabetes Mellitus, Insulin Resistance","enrollment":14},{"nctId":"NCT02377388","phase":"PHASE3","title":"DPP-4 Inhibitors and Acute Myocardial Infarction:Effects on Platelet Function","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2017-02-07","conditions":"Platelet Aggregation During Acute Myocardial Infarction","enrollment":74},{"nctId":"NCT02419612","phase":"PHASE3","title":"A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-14","conditions":"Diabetes","enrollment":444},{"nctId":"NCT02965443","phase":"PHASE4","title":"Dapagliflozin + Saxagliptin in a Basal-bolus Insulin Treatment","status":"TERMINATED","sponsor":"University Hospital Tuebingen","startDate":"2018-02-02","conditions":"Type 2 Diabetes","enrollment":4},{"nctId":"NCT01548651","phase":"PHASE4","title":"Effect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte Inflammation","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2012-02","conditions":"Impaired Glucose Tolerance","enrollment":8},{"nctId":"NCT01922817","phase":"PHASE3","title":"DPP4inhibitors in Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2012-09","conditions":"Type 1 Diabetes, Hypoglycaemia","enrollment":28},{"nctId":"NCT02547935","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09-21","conditions":"Type 2 Diabetes Mellitus, CKD and Albuminuria","enrollment":459},{"nctId":"NCT02613897","phase":"NA","title":"ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2016-01","conditions":"Diabetes Mellitus, Type 2","enrollment":56},{"nctId":"NCT03933787","phase":"EARLY_PHASE1","title":"Neuropeptide Y and Sympathovagal Balance","status":"COMPLETED","sponsor":"Eric Grouzmann","startDate":"2018-06-05","conditions":"Physical Activity, Sympathetic Nervous System, Secretion; Catecholamine","enrollment":7},{"nctId":"NCT02471404","phase":"PHASE4","title":"Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09-21","conditions":"Type 2 Diabetes Mellitus, Inadequate Glycaemic Control","enrollment":939},{"nctId":"NCT02024477","phase":"PHASE4","title":"Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients","status":"COMPLETED","sponsor":"George Washington University","startDate":"2013-11","conditions":"Type 2 Diabetes","enrollment":42},{"nctId":"NCT02681094","phase":"PHASE3","title":"A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-02-26","conditions":"Type 2 Diabetes Mellitus, Inadequate Glycaemic Control","enrollment":905},{"nctId":"NCT02104739","phase":"PHASE4","title":"Effects of Antidiabetic Medications on the Postprandial State in Prediabetes","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2014-04","conditions":"Prediabetes, Obesity","enrollment":21},{"nctId":"NCT02304081","phase":"PHASE4","title":"Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function","status":"COMPLETED","sponsor":"Prof. Dr. Thomas Forst","startDate":"2015-01","conditions":"Type2 Diabetes Mellitus","enrollment":64},{"nctId":"NCT02284893","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09-09","conditions":"Type 2 Diabetes","enrollment":461},{"nctId":"NCT02273050","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12","conditions":"Type 2 Diabetes Mellitus","enrollment":1136},{"nctId":"NCT02104804","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-05-07","conditions":"Type 2 Diabetes Mellitus","enrollment":953},{"nctId":"NCT02742233","phase":"PHASE4","title":"Dipeptidyl Peptidase 4 Inhibition Facilitate Healing of Diabetic Ulcers","status":"UNKNOWN","sponsor":"Long Min,MD","startDate":"2015-11","conditions":"Diabetic Foot Ulcer","enrollment":60},{"nctId":"NCT01582308","phase":"PHASE1","title":"A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-06-21","conditions":"Type 2 Diabetes Mellitus","enrollment":22},{"nctId":"NCT01606007","phase":"PHASE3","title":"Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-07","conditions":"Type 2 Diabetes","enrollment":1282},{"nctId":"NCT01204775","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-06","conditions":"Type 2 Diabetes","enrollment":26},{"nctId":"NCT01434186","phase":"PHASE3","title":"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-05","conditions":"Diabetes Mellitus, Type 2","enrollment":32},{"nctId":"NCT00857558","phase":"PHASE2","title":"A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2009-01","conditions":"Diabetes, Type 2","enrollment":350},{"nctId":"NCT01192659","phase":"","title":"Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-05","conditions":"Diabetes Mellitus, Type 2","enrollment":16492},{"nctId":"NCT01646320","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-09","conditions":"Type 2 Diabetes","enrollment":320},{"nctId":"NCT01619059","phase":"PHASE3","title":"Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-06","conditions":"Type 2 Diabetes","enrollment":315},{"nctId":"NCT00683657","phase":"PHASE3","title":"Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-07","conditions":"Type 2 Diabetes","enrollment":93},{"nctId":"NCT00885378","phase":"PHASE3","title":"Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-05","conditions":"Type 2 Diabetes Mellitus","enrollment":166},{"nctId":"NCT00757588","phase":"PHASE3","title":"Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-11","conditions":"Type 2 Diabetes","enrollment":455},{"nctId":"NCT01765270","phase":"PHASE4","title":"Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery","status":"TERMINATED","sponsor":"Duke University","startDate":"2013-03","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Disease","enrollment":12},{"nctId":"NCT00918138","phase":"PHASE3","title":"Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-08","conditions":"Type 2 Diabetes","enrollment":219},{"nctId":"NCT00374907","phase":"PHASE3","title":"A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Type 2 Diabetes","enrollment":156},{"nctId":"NCT00313313","phase":"PHASE3","title":"A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-04","conditions":"Diabetes","enrollment":768},{"nctId":"NCT00316082","phase":"PHASE3","title":"Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-06","conditions":"Diabetes","enrollment":365},{"nctId":"NCT00327015","phase":"PHASE3","title":"A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-05","conditions":"Diabetes","enrollment":1306},{"nctId":"NCT00121667","phase":"PHASE3","title":"Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-08","conditions":"Diabetes Mellitus, Type 2","enrollment":1462},{"nctId":"NCT02239458","phase":"NA","title":"DPP-IV Inhibition Prior to Development of Diabetes in Patients With Cystic Fibrosis","status":"UNKNOWN","sponsor":"Ram Weiss","startDate":"2015-06","conditions":"Cystic Fibrosis","enrollment":60},{"nctId":"NCT00295633","phase":"PHASE3","title":"A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-03","conditions":"Diabetes Mellitus, Type 2","enrollment":565},{"nctId":"NCT00121641","phase":"PHASE3","title":"Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-07","conditions":"Diabetes Mellitus, Type 2","enrollment":1035},{"nctId":"NCT00950599","phase":"PHASE2","title":"Study of Multiple Doses of Saxagliptin (BMS-477118)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-05","conditions":"Type 2 Diabetes Mellitus","enrollment":423},{"nctId":"NCT01521312","phase":"PHASE2","title":"ACute and Chronic Effects of Saxagliptin","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-09","conditions":"Impaired Glucose Tolerance","enrollment":24},{"nctId":"NCT01107886","phase":"PHASE4","title":"Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-05","conditions":"Type 2 Diabetes Mellitus","enrollment":18206},{"nctId":"NCT01552018","phase":"PHASE4","title":"Saxagliptin and Atherosclerosis","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2012-03","conditions":"Coronary Artery Disease, Diabetes Mellitus Type 2","enrollment":12},{"nctId":"NCT01319357","phase":"PHASE3","title":"Effects of Saxagliptin on Endothelial Function","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2010-10","conditions":"Diabetes Mellitus Type 2","enrollment":52},{"nctId":"NCT01128153","phase":"PHASE3","title":"Saxagliptin Triple Oral Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-06","conditions":"Type 2 Diabetes","enrollment":257},{"nctId":"NCT00661362","phase":"PHASE3","title":"Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-06","conditions":"Type 2 Diabetes","enrollment":570},{"nctId":"NCT00918879","phase":"PHASE3","title":"Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-05","conditions":"Type 2 Diabetes","enrollment":213},{"nctId":"NCT00698932","phase":"PHASE3","title":"Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-06","conditions":"Type 2 Diabetes","enrollment":568},{"nctId":"NCT00614939","phase":"PHASE3","title":"Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-01","conditions":"Type 2 Diabetes","enrollment":572}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"RENAL FAILURE ACUTE"}],"_approvalHistory":[],"publicationCount":195,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo (Saxagliptin)","genericName":"Placebo (Saxagliptin)","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which works by increasing the levels of incretin hormones to stimulate the release of insulin and decrease the release of glucagon. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}